About Clearmind Medicine Common Shares
Clearmind Medicine (NASDAQ:CMND) is a biotech company focused on discovering and developing novel treatments for mental health and substance use disorders. Their operations revolve around pioneering psychedelic-based therapies, aiming to address the significant unmet needs in the mental health care sector. With an innovative approach, their projects include developing CMND-100, a potential treatment for alcohol use disorder, alongside exploring other compounds for various psychological conditions. Their objective is to revolutionize the therapeutic landscape by providing safer, more effective alternatives to current treatments, ultimately improving patient outcomes and well-being. Clearmind is committed to pushing the boundaries of psychiatric care, advancing research, and opening new pathways for those struggling with mental health issues.
Snapshot
Operations
Products and/or services of Clearmind Medicine Common Shares
- Development of CMND-100, a novel psychedelic compound aimed at treating alcohol use disorder.
- Research into novel therapy-assisted models to improve mental health treatment outcomes.
- Exploration of psychedelic-based treatments for addressing major depressive disorder.
- Innovation in non-invasive technologies for delivering mental health therapies.
- Partnerships for clinical trials to expand understanding of psychedelic compounds' efficacy.
- Outreach programs designed to educate the public and healthcare providers about the potential benefits of psychedelics in mental health treatment.
Clearmind Medicine Common Shares executive team
- Dr. Adi Zuloff-Shani Ph.D.Chief Executive Officer
- Mr. Alan Mark Rootenberg B.Com., B.Comm, C.A., CPAChief Financial Officer
- Prof. Mark Haden M.S.W.Vice President of Business Development
- Ms. Mylene TouboulAccounting Manager
- Ms. Mary-Elizabeth GiffordChief of Global Impact
- Ms. Adi VaronController